FR2421905A1 - Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution - Google Patents

Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution

Info

Publication number
FR2421905A1
FR2421905A1 FR7735430A FR7735430A FR2421905A1 FR 2421905 A1 FR2421905 A1 FR 2421905A1 FR 7735430 A FR7735430 A FR 7735430A FR 7735430 A FR7735430 A FR 7735430A FR 2421905 A1 FR2421905 A1 FR 2421905A1
Authority
FR
France
Prior art keywords
degrees
prepn
alkanol
soln
reconstitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7735430A
Other languages
French (fr)
Other versions
FR2421905B1 (en
Inventor
Michael David Cise
Michael Larry Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to FR7735430A priority Critical patent/FR2421905A1/en
Publication of FR2421905A1 publication Critical patent/FR2421905A1/en
Application granted granted Critical
Publication of FR2421905B1 publication Critical patent/FR2421905B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Prepn. of crystalline sodium cephalothin by a freeze-drying process of 24h comprising (a) dissolving 20-40 wt.% of sodium cephalothin in water contg. 2-10% of a 1-3C alkanol or acetone (b) cooling the soln. to =-20 degrees C (c) heating the soln. to -3 to -10 degrees c, (d) maintaining the soln. at -3 to -10 degrees C for >=3 hr, (e) cooling the soln. to =-20 degrees C, (f) reducing the pressure in the vessel to =1mm Hg, (g) raising the temp. of the vessel to =50 degrees C, without melting the prepn. (h) subliming the solvent to give crystalline sodium cephalothin with a moisture content of =1% and an alkanol or acetone content of =1%. The products are suitable for reconstitution and use as parenteral injections. The rapid cooling to -20 degrees C forms crystals of sodium cephalothin before the solvent is frozen. When the solvent is sublimed the residue remains as crystals. When the initial soln. (a) is sterile, the product is a sterile crystal ready for prepn. of parenteral solns.
FR7735430A 1977-11-24 1977-11-24 Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution Granted FR2421905A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7735430A FR2421905A1 (en) 1977-11-24 1977-11-24 Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7735430A FR2421905A1 (en) 1977-11-24 1977-11-24 Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution

Publications (2)

Publication Number Publication Date
FR2421905A1 true FR2421905A1 (en) 1979-11-02
FR2421905B1 FR2421905B1 (en) 1981-03-06

Family

ID=9198026

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7735430A Granted FR2421905A1 (en) 1977-11-24 1977-11-24 Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution

Country Status (1)

Country Link
FR (1) FR2421905A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2306993A1 (en) * 1975-04-11 1976-11-05 Lilly Co Eli PROCESS FOR THE PREPARATION OF CRYSTALLINE, STERILE AND STABLE CEPHALOSPORINS FOR PARENTERAL ADMINISTRATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2306993A1 (en) * 1975-04-11 1976-11-05 Lilly Co Eli PROCESS FOR THE PREPARATION OF CRYSTALLINE, STERILE AND STABLE CEPHALOSPORINS FOR PARENTERAL ADMINISTRATION

Also Published As

Publication number Publication date
FR2421905B1 (en) 1981-03-06

Similar Documents

Publication Publication Date Title
DE3279807D1 (en) Process for heat treatment of aqueous solution containing human blood coagulation factor viii
IE42955L (en) Sterile crystalline cephalosporins
GB1044649A (en) Improvements in or relating to the preservation of blood
NL7712822A (en) Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution
FR2421905A1 (en) Stable, crystalline sodium cephalothin prepn. - by freeze-drying aq. alkanol or aq. acetone solns.; used for parenteral injection, after reconstitution
KR890006243A (en) Antibiotic solution and its lyophilization method
ES464412A1 (en) Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration
IE34424B1 (en) Isolation of proteins
Goldner et al. Further Studies on the Mechanism of Alloxan Diabetes, Pancreatectomy and Alloxan.
ES455069A1 (en) Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPH0374643B2 (en)
GB838939A (en) Regeneration of degraded alkyl anthraquinone solutions for the production of hydrogen peroxide
US2365777A (en) 6-iodo-d-galactose
Britton et al. Some observations on the cortico-adrenal hormone
Nelson The anti-insulin action of anterior pituitary extracts.
JPS56127321A (en) Preparation of gamma-globulin pharmaceutical
US2639287A (en) Thiosemicarbazones of furylketones
US3060102A (en) Method of purifying streptokinase
ES8301470A1 (en) Improvements in or relating to a process for recovering material from a solution
US3129214A (en) Method for crystallizing monosodium novobiocin
SU1066558A1 (en) Method of protection of myocardium from ischemia
US2486181A (en) Process of preparing crystalline salts of penicillin
GB1346319A (en) Artificial insemination of sows
GB1176821A (en) Sulphomethyl Derivatives of Polymyxin B.
GB733268A (en) Improvements in or relating to process for purification of tyrosine

Legal Events

Date Code Title Description
ST Notification of lapse